{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:49:06Z","timestamp":1785908946888,"version":"3.56.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102580","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:55:40Z","timestamp":1779429340000},"page":"102580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Tumor Microenvironment Inflammatory Biomarkers in Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3378-9270","authenticated-orcid":false,"given":"Lars","family":"Dr\u00fcke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9843-7339","authenticated-orcid":false,"given":"Jessica","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2961-0801","authenticated-orcid":false,"given":"Manuel M.","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Vasileiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4071-5866","authenticated-orcid":false,"given":"David","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Maulhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus A.","family":"Kuczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Tezval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2532-8398","authenticated-orcid":false,"given":"Christopher","family":"Darr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-7687","authenticated-orcid":false,"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-7302","authenticated-orcid":false,"given":"Philipp","family":"Ivanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-3067","authenticated-orcid":false,"given":"Jan H.","family":"Br\u00e4sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clgc.2026.102580_bib0001","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102580_bib0002","article-title":"Tumor associated macrophages in kidney cancer","volume":"2016","author":"Kovaleva","year":"2016","journal-title":"Anal Cell Pathol (Amst)"},{"key":"10.1016\/j.clgc.2026.102580_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2025 update","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102580_bib0004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN guidelines\u00ae insights: kidney cancer, version 2.2024: featured updates to the NCCN guidelines","volume":"22","author":"Motzer","year":"2024","journal-title":"J Natl Compr Cancer Netwk"},{"issue":"8","key":"10.1016\/j.clgc.2026.102580_bib0005","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102580_bib0006","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41581-020-0316-3","article-title":"The immunology of renal cell carcinoma","volume":"16","author":"D\u00edaz-Montero","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102580_bib0007","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102580_bib0008","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/2159-8290.CD-19-0499","article-title":"Tumor microenvironment dynamics in clear-cell renal cell carcinoma","volume":"9","author":"Vuong","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.clgc.2026.102580_bib0009","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","article-title":"Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures","volume":"17","author":"\u015eenbabao\u011flu","year":"2016","journal-title":"Genome Biol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102580_bib0010","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.cell.2017.04.016","article-title":"An immune atlas of clear cell renal cell carcinoma","volume":"169","author":"Chevrier","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.clgc.2026.102580_bib0011","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.clgc.2026.102580_bib0012","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","article-title":"The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters","volume":"37","author":"Delahunt","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2026.102580_bib0013","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"issue":"18","key":"10.1016\/j.clgc.2026.102580_bib0014","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2026.102580_bib0015","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102580_bib0016","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"10189","key":"10.1016\/j.clgc.2026.102580_bib0017","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clgc.2026.102580_bib0018","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"issue":"20","key":"10.1016\/j.clgc.2026.102580_bib0019","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clgc.2026.102580_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.clgc.2026.102580_bib0021","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4103\/0256-4947.51806","article-title":"Tissue microarray: a rapidly evolving diagnostic and research tool","volume":"29","author":"Jawhar","year":"2009","journal-title":"Ann Saudi Med"},{"issue":"2","key":"10.1016\/j.clgc.2026.102580_bib0022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102580_bib0023","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull"},{"key":"10.1016\/j.clgc.2026.102580_bib0024","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.clgc.2026.102580_bib0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12935-019-0957-0","article-title":"Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients","volume":"19","author":"Yuan","year":"2019","journal-title":"Cancer Cell Int"},{"issue":"3","key":"10.1016\/j.clgc.2026.102580_bib0026","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00432-020-03477-3","article-title":"Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer","volume":"147","author":"Fu","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102580_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.768115","article-title":"Significance of CD47 and its association with tumor immune microenvironment heterogeneity in ovarian cancer","volume":"12","author":"Yu","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102580_bib0028","doi-asserted-by":"crossref","first-page":"166.e15","DOI":"10.1016\/j.urolonc.2021.11.024","article-title":"Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients","volume":"40","author":"Jiang","year":"2022","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102580_bib0029","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.3390\/diagnostics12102291","article-title":"CD47 expression predicts unfavorable prognosis in clear cell renal cell carcinoma after curative resection","volume":"12","author":"Park","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"10.1016\/j.clgc.2026.102580_bib0030","first-page":"179","article-title":"Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment","volume":"3","author":"Kaur","year":"2020","journal-title":"Antib Ther"},{"issue":"1","key":"10.1016\/j.clgc.2026.102580_bib0031","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-sirp\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"issue":"7791","key":"10.1016\/j.clgc.2026.102580_bib0032","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2026.102580_bib0033","article-title":"CD20+CD22+ADAM28+ B cells in tertiary lymphoid structures promote immunotherapy response","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.clgc.2026.102580_bib0034","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1158\/1078-0432.CCR-21-0697","article-title":"Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.clgc.2026.102580_bib0035","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1158\/1078-0432.CCR-14-2926","article-title":"Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer","volume":"21","author":"Giraldo","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2026.102580_bib0036","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/cei.13567","article-title":"Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response","volume":"204","author":"Hajiran","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"21","key":"10.1016\/j.clgc.2026.102580_bib0037","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2217\/fon-2023-1068","article-title":"Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)","volume":"20","author":"Catalano","year":"2024","journal-title":"Future Oncol"},{"issue":"23","key":"10.1016\/j.clgc.2026.102580_bib0039","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","article-title":"Renal-cell carcinoma","volume":"353","author":"Cohen","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2026.102580_bib0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00428-022-03323-6","article-title":"Assessing the prognostic value of tumor-infiltrating CD57+ cells in advanced stage head and neck cancer using QuPath digital image analysis","volume":"481","author":"de Ruiter","year":"2022","journal-title":"Virchows Arch"},{"issue":"8","key":"10.1016\/j.clgc.2026.102580_bib0041","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.7150\/jca.63008","article-title":"Prognostic impact of tumor budding in intrahepatic cholangiocellular carcinoma","volume":"13","author":"Budau","year":"2022","journal-title":"J Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2026.102580_bib0042","doi-asserted-by":"crossref","DOI":"10.1177\/1010428320971404","article-title":"Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer","volume":"42","author":"Jantti","year":"2020","journal-title":"Tumour Biol"},{"key":"10.1016\/j.clgc.2026.102580_bib0043","article-title":"Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma","author":"Marchenko","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102580_bib0044","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0438-3","article-title":"RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer","volume":"6","author":"Ledys","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2026.102580_bib0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/jpi.jpi_76_20","article-title":"Digital pathology-based study of cell- and tissue-level morphologic features in serous borderline ovarian tumor and high-grade serous ovarian cancer","volume":"12","author":"Jiang","year":"2021","journal-title":"J Pathol Inform"},{"issue":"5","key":"10.1016\/j.clgc.2026.102580_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.03.007","article-title":"Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy","volume":"39","author":"Krishna","year":"2021","journal-title":"Cancer Cell"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:20:58Z","timestamp":1785907258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1558767326000807"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102580","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Tumor Microenvironment Inflammatory Biomarkers in Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102580"}}